SG10202012498TA - Compounds useful as kinase inhibitors - Google Patents

Compounds useful as kinase inhibitors

Info

Publication number: SG10202012498TA
Authority: SG; Singapore
Prior art keywords: kinase inhibitors; compounds useful; compounds; useful; kinase
Prior art date: 2015-12-16

Application number

SG10202012498TA

Inventor

Nicolas Guisot

Original Assignee

Loxo Oncology Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-12-16

Filing date

2016-12-16

Publication date

2021-01-28

2015-12-16 Priority claimed from GBGB1522245.8A external-priority patent/GB201522245D0/en

2016-08-15 Priority claimed from GBGB1613945.3A external-priority patent/GB201613945D0/en

2016-12-16 Application filed by Loxo Oncology Inc filed Critical Loxo Oncology Inc

2021-01-28 Publication of SG10202012498TA publication Critical patent/SG10202012498TA/en

Links

150000001875 compounds Chemical class 0.000 title 1
229940043355 kinase inhibitor Drugs 0.000 title 1
239000003757 phosphotransferase inhibitor Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/08—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing alicyclic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

SG10202012498TA 2015-12-16 2016-12-16 Compounds useful as kinase inhibitors SG10202012498TA (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB1522245.8A GB201522245D0 (en)	2015-12-16	2015-12-16	Compounds useful as kinase inhibitors
GBGB1613945.3A GB201613945D0 (en)	2016-08-15	2016-08-15	Compounds useful as kinase inhibitors

Publications (1)

Publication Number	Publication Date
SG10202012498TA true SG10202012498TA (en)	2021-01-28

Family

ID=57590725

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
SG11201805044WA SG11201805044WA (en)	2015-12-16	2016-12-16	Compounds useful as kinase inhibitors
SG10202012498TA SG10202012498TA (en)	2015-12-16	2016-12-16	Compounds useful as kinase inhibitors

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
SG11201805044WA SG11201805044WA (en)	2015-12-16	2016-12-16	Compounds useful as kinase inhibitors

Country Status (34)

Country	Link
US (7)	US10695323B2 (en)
EP (2)	EP3782994A1 (en)
JP (3)	JP6731483B2 (en)
KR (2)	KR20210018530A (en)
CN (9)	CN114591242A (en)
AU (4)	AU2016373530B2 (en)
CA (1)	CA3008488C (en)
CL (1)	CL2018001591A1 (en)
CO (1)	CO2018006164A2 (en)
CR (1)	CR20180367A (en)
CY (1)	CY1123561T1 (en)
DK (1)	DK3390395T3 (en)
EA (1)	EA035132B1 (en)
ES (1)	ES2828431T3 (en)
FI (1)	FIC20240004I1 (en)
HK (1)	HK1263254A1 (en)
HR (1)	HRP20201835T1 (en)
HU (2)	HUE051921T2 (en)
IL (4)	IL285976B2 (en)
LT (1)	LT3390395T (en)
MA (2)	MA55064A (en)
MD (1)	MD3390395T2 (en)
MX (2)	MX2018007267A (en)
NZ (1)	NZ743553A (en)
PE (3)	PE20220507A1 (en)
PH (1)	PH12018501268A1 (en)
PT (1)	PT3390395T (en)
RS (1)	RS60982B1 (en)
SG (2)	SG11201805044WA (en)
SI (1)	SI3390395T1 (en)
TN (1)	TN2018000213A1 (en)
UA (2)	UA127863C2 (en)
WO (1)	WO2017103611A1 (en)
ZA (4)	ZA201804137B (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB201410430D0 (en)	2014-06-11	2014-07-23	Redx Pharma Ltd	Compounds
EP4116303A1 (en)	2015-09-16	2023-01-11	Loxo Oncology, Inc.	Pyrazolopyrimidine derivatives as btk inhibitors for the treatment of cancer
CR20180367A (en)	2015-12-16	2018-11-12	Loxo Oncology Inc [	USEFUL COMPOUNDS AS KINASE INHIBITORS
GB201801226D0 (en)	2018-01-25	2018-03-14	Redx Pharma Plc	Modulators of Rho-associated protein kinase
MX2020010469A (en) *	2018-04-06	2021-04-19	Praxis Biotech LLC	Atf6 inhibitors and uses thereof.
JP6995195B2 (en)	2018-05-18	2022-02-04	富士フイルム株式会社	A method for producing a 3-difluoromethylpyrazole compound, a method for producing a 3-difluoromethylpyrazole-4-carboxylic acid compound, and a pyrazolidine compound.
EP3829543A1 (en)	2018-07-31	2021-06-09	Loxo Oncology, Inc.	Spray-dried dispersions and formulations of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoro propan-2-yl)-1h-pyrazole-4-carboxamide
CN114206852A (en)	2019-08-09	2022-03-18	卡尔维斯塔制药有限公司	Plasma kallikrein inhibitors
WO2021053234A1 (en) *	2019-09-19	2021-03-25	Johann Wolfgang Goethe-Universität Frankfurt am Main	Compounds and compositions for treating kidney disease
CN110724135B (en) *	2019-11-18	2023-04-28	上海医药工业研究院有限公司	Esalapril Lin Zhongjian body and preparation method thereof
US20230041515A1 (en) *	2019-12-06	2023-02-09	Loxo Oncology, Inc.	Dosing of a bruton's tyrosine kinase inhibitor
US20230145305A1 (en) *	2020-03-12	2023-05-11	Fochon Biosciences, Ltd.	Compounds useful as kinase inhibitors
TWI809489B (en) *	2020-09-10	2023-07-21	美商絡速藥業公司	Processes and intermediates for the preparation of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropane-2-yl)-1h-pyrazole-4-carboxamide
CN112386597B (en) *	2020-10-15	2022-03-15	天津济坤医药科技有限公司	Application of zebritinib in preparation of medicine for treating pulmonary fibrosis diseases
WO2022140246A1 (en)	2020-12-21	2022-06-30	Hangzhou Jijing Pharmaceutical Technology Limited	Methods and compounds for targeted autophagy
CN116348453A (en) *	2021-04-25	2023-06-27	烨辉医药科技(上海)有限公司	Heteroaromatic carboxamide compounds and uses thereof
BR112023021235A2 (en)	2021-05-14	2023-12-12	Loxo Oncology Inc	CO-CRYSTALLINE FORMS OF A BRUTON'S TYROSINE KINASE INHIBITOR
CN115557933A (en) *	2021-07-01	2023-01-03	杭州和正医药有限公司	Bruton tyrosine kinase and mutant degradation agent, composition and application thereof
WO2023284765A1 (en) *	2021-07-16	2023-01-19	深圳市塔吉瑞生物医药有限公司	Substituted pyrazole compound, composition containing same and use thereof
WO2023110970A1 (en)	2021-12-14	2023-06-22	Netherlands Translational Research Center Holding B.V	Macrocyclic btk inhibitors
WO2023143355A1 (en) *	2022-01-28	2023-08-03	Hansoh Bio Llc	Azacycle amide derivative, preparation methods and medicinal uses thereof
WO2023174397A1 (en) *	2022-03-18	2023-09-21	Insilico Medicine Ip Limited	Pyrazole membrane-associated tyrosine-and threonine-specific cdc2-inhibitory kinase (pkmyt1) inhibitors and uses thereof
CN115894376A (en) *	2022-12-15	2023-04-04	南京雷正医药科技有限公司	Aromatic amide compound, pharmaceutical composition and application thereof

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2385747A1 (en)	1999-09-17	2001-03-22	Gavin C. Hirst	Pyrazolopyrimidines as therapeutic agents
US6921763B2 (en)	1999-09-17	2005-07-26	Abbott Laboratories	Pyrazolopyrimidines as therapeutic agents
US6291504B1 (en) *	1999-10-20	2001-09-18	Dupont Pharmaceuticals Company	Acylsemicarbazides and their uses
US20030225098A1 (en)	2002-03-21	2003-12-04	Hirst Gavin C.	Kinase inhibitors
HUE031334T2 (en)	2006-09-22	2017-07-28	Pharmacyclics Llc	Inhibitors of bruton's tyrosine kinase
CN101553224A (en) *	2006-10-06	2009-10-07	艾博特公司	Novel imidazothiazoles and imidazoxazoles
US8987233B2 (en)	2006-11-03	2015-03-24	Pharmacyclics, Inc.	Bruton's tyrosine kinase activity probe and method of using
SG10202107066WA (en)	2007-03-28	2021-07-29	Pharmacyclics Llc	Inhibitors of bruton's tyrosine kinase
US8338439B2 (en)	2008-06-27	2012-12-25	Celgene Avilomics Research, Inc.	2,4-disubstituted pyrimidines useful as kinase inhibitors
RU2536584C2 (en)	2008-06-27	2014-12-27	Авила Терапьютикс, Инк.	Heteroaryl compounds and using them
EP3311818A3 (en)	2008-07-16	2018-07-18	Pharmacyclics, LLC	Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
US8541575B2 (en) *	2008-07-24	2013-09-24	Nerviano Medical Sciences S.R.L.	3,4-diarylpyrazoles as protein kinase inhibitors
US8426428B2 (en)	2008-12-05	2013-04-23	Principia Biopharma, Inc.	EGFR kinase knockdown via electrophilically enhanced inhibitors
US7718662B1 (en)	2009-10-12	2010-05-18	Pharmacyclics, Inc.	Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
CN107898791A (en)	2010-06-03	2018-04-13	药品循环有限责任公司	The application of bruton's tyrosine kinase (BTK) inhibitor
MX2012015252A (en)	2010-06-30	2013-05-30	Ironwood Pharmaceuticals Inc	Sgc stimulators.
CA2836410C (en)	2011-05-17	2019-08-20	Principia Biopharma Inc.	Tyrosine kinase inhibitors
KR102052670B1 (en)	2011-05-17	2019-12-06	더 리젠츠 오브 더 유니버시티 오브 캘리포니아	Kinase inhibitors
KR20140048968A (en)	2011-07-13	2014-04-24	파마시클릭스, 인코포레이티드	Inhibitors of bruton's tyrosine kinase
EP2548877A1 (en)	2011-07-19	2013-01-23	MSD Oss B.V.	4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
US8377946B1 (en)	2011-12-30	2013-02-19	Pharmacyclics, Inc.	Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
CN104487441B (en)	2012-06-18	2018-06-01	普林斯匹亚生物制药公司	It is useful for the reversible covalent pyrrolopyrimidine or pyrazolopyrimidine for the treatment of cancer and autoimmune disease
US9572811B2 (en)	2012-08-03	2017-02-21	Principia Biopharma Inc.	Treatment of dry eye
SG11201500499TA (en) *	2012-08-10	2015-03-30	Boehringer Ingelheim Int	Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors
GB201214750D0 (en) *	2012-08-17	2012-10-03	Respivert Ltd	Compounds
GEP201606597B (en) *	2012-11-02	2017-01-10	Pfizer	Bruton's tyrosine kinase inhibitors
CN103848810A (en) *	2012-11-30	2014-06-11	北京赛林泰医药技术有限公司	Bruton's tyrosine kinases inhibitor
US8957080B2 (en)	2013-04-09	2015-02-17	Principia Biopharma Inc.	Tyrosine kinase inhibitors
GB201309085D0 (en)	2013-05-20	2013-07-03	Redx Pharma Ltd	Compounds
CN104341388B (en) *	2013-10-16	2017-03-22	北京诺诚健华医药科技有限公司	Aromatic amide derivative as well as preparation method and medicinal application thereof
WO2015075051A1 (en) *	2013-11-19	2015-05-28	Universitaet Des Saarlandes	Allosteric inhibitors of atypical protein kinases c
EP3082809B1 (en)	2013-12-20	2021-01-20	Merck Sharp & Dohme Corp.	Btk inhibitors
MX2016010754A (en)	2014-02-21	2017-03-03	Principia Biopharma Inc	Salts and solid form of a btk inhibitor.
GB201404987D0 (en)	2014-03-20	2014-05-07	Redx Pharma Ltd	Compounds
CN105085474B (en)	2014-05-07	2018-05-18	北京赛林泰医药技术有限公司	Shandong tyrosine kinase inhibitor
GB201410430D0 (en)	2014-06-11	2014-07-23	Redx Pharma Ltd	Compounds
BR112017016193B1 (en)	2015-01-28	2023-02-23	Bayer Pharma Aktiengesellschaft	4H-PYROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES
GB2548542A (en) *	2015-06-16	2017-09-27	Redx Pharma Plc	Compounds
JOP20160198B1 (en)	2015-09-16	2022-03-14	Janssen Pharmaceuticals Inc	Mono- or di-substituted indole derivatives as dengue viral replication inhibitors
EP4116303A1 (en)	2015-09-16	2023-01-11	Loxo Oncology, Inc.	Pyrazolopyrimidine derivatives as btk inhibitors for the treatment of cancer
JO3633B1 (en)	2015-09-16	2020-08-27	Katholieke Univ Leuven Ku Leuven Research & Development	Mono- or di-substituted indole derivatives as dengue viral replication inhibitors
DK3390390T3 (en)	2015-12-16	2021-12-06	Boehringer Ingelheim Int	Bipyrazolyl derivatives suitable for the treatment of autoimmune diseases
US10981858B2 (en)	2015-12-16	2021-04-20	Priostar Pty Ltd	Dendrimer and formulations thereof
EP3389831A4 (en)	2015-12-16	2019-07-31	Ecolab USA Inc.	Peroxyformic acid compositions for membrane filtration cleaning
CN108602813B (en)	2015-12-16	2021-10-29	百时美施贵宝公司	Heteroaryl hydroxypyrimidinones as APJ receptor agonists
CR20180367A (en)	2015-12-16	2018-11-12	Loxo Oncology Inc [	USEFUL COMPOUNDS AS KINASE INHIBITORS

2016
- 2016-12-16 CR CR20180367A patent/CR20180367A/en unknown
- 2016-12-16 CN CN202210312050.8A patent/CN114591242A/en active Pending
- 2016-12-16 TN TNP/2018/000213A patent/TN2018000213A1/en unknown
- 2016-12-16 NZ NZ743553A patent/NZ743553A/en unknown
- 2016-12-16 CN CN202111022492.0A patent/CN113636978A/en active Pending
- 2016-12-16 WO PCT/GB2016/053968 patent/WO2017103611A1/en active Application Filing
- 2016-12-16 EP EP20194724.9A patent/EP3782994A1/en active Pending
- 2016-12-16 KR KR1020217003683A patent/KR20210018530A/en active Application Filing
- 2016-12-16 DK DK16816363.2T patent/DK3390395T3/en active
- 2016-12-16 EA EA201891268A patent/EA035132B1/en not_active IP Right Cessation
- 2016-12-16 KR KR1020187020225A patent/KR102215792B1/en active IP Right Grant
- 2016-12-16 MX MX2018007267A patent/MX2018007267A/en unknown
- 2016-12-16 UA UAA202003795A patent/UA127863C2/en unknown
- 2016-12-16 US US16/063,542 patent/US10695323B2/en active Active
- 2016-12-16 CN CN202210311970.8A patent/CN114573510A/en active Pending
- 2016-12-16 SI SI201630920T patent/SI3390395T1/en unknown
- 2016-12-16 CN CN202210312064.XA patent/CN114605327A/en active Pending
- 2016-12-16 EP EP16816363.2A patent/EP3390395B1/en active Active
- 2016-12-16 CN CN202210312076.2A patent/CN114621146A/en active Pending
- 2016-12-16 MD MDE20181001T patent/MD3390395T2/en unknown
- 2016-12-16 CO CONC2018/0006164A patent/CO2018006164A2/en unknown
- 2016-12-16 PT PT168163632T patent/PT3390395T/en unknown
- 2016-12-16 MA MA055064A patent/MA55064A/en unknown
- 2016-12-16 LT LTEP16816363.2T patent/LT3390395T/en unknown
- 2016-12-16 AU AU2016373530A patent/AU2016373530B2/en active Active
- 2016-12-16 MA MA49809A patent/MA49809A1/en unknown
- 2016-12-16 JP JP2018532035A patent/JP6731483B2/en active Active
- 2016-12-16 UA UAA201807294A patent/UA122258C2/en unknown
- 2016-12-16 HU HUE16816363A patent/HUE051921T2/en unknown
- 2016-12-16 CN CN202210310724.0A patent/CN114716381A/en active Pending
- 2016-12-16 SG SG11201805044WA patent/SG11201805044WA/en unknown
- 2016-12-16 ES ES16816363T patent/ES2828431T3/en active Active
- 2016-12-16 IL IL285976A patent/IL285976B2/en unknown
- 2016-12-16 CN CN202111022488.4A patent/CN113603645A/en active Pending
- 2016-12-16 PE PE2021001581A patent/PE20220507A1/en unknown
- 2016-12-16 PE PE2021001592A patent/PE20220502A1/en unknown
- 2016-12-16 RS RS20201291A patent/RS60982B1/en unknown
- 2016-12-16 CA CA3008488A patent/CA3008488C/en active Active
- 2016-12-16 CN CN202210311995.8A patent/CN114634447A/en active Pending
- 2016-12-16 PE PE2018001143A patent/PE20181449A1/en unknown
- 2016-12-16 CN CN201680073031.7A patent/CN108473481B/en active Active
- 2016-12-16 SG SG10202012498TA patent/SG10202012498TA/en unknown
- 2016-12-16 MX MX2021003478A patent/MX2021003478A/en unknown
2018
- 2018-06-10 IL IL259923A patent/IL259923B/en active IP Right Grant
- 2018-06-13 PH PH12018501268A patent/PH12018501268A1/en unknown
- 2018-06-14 CL CL2018001591A patent/CL2018001591A1/en unknown
- 2018-06-20 ZA ZA2018/04137A patent/ZA201804137B/en unknown
- 2018-08-22 US US16/109,162 patent/US10342780B2/en active Active
- 2018-08-27 US US16/113,661 patent/US10464905B2/en active Active
- 2018-11-06 HK HK18114157.0A patent/HK1263254A1/en unknown
2020
- 2020-05-13 US US15/930,657 patent/US10918622B2/en active Active
- 2020-07-06 JP JP2020116636A patent/JP7086140B2/en active Active
- 2020-07-26 IL IL276283A patent/IL276283B/en active IP Right Grant
- 2020-11-16 CY CY20201101090T patent/CY1123561T1/en unknown
- 2020-11-19 HR HRP20201835TT patent/HRP20201835T1/en unknown
- 2020-12-15 US US17/122,103 patent/US11471441B2/en active Active
2021
- 2021-01-26 ZA ZA2021/00544A patent/ZA202100544B/en unknown
- 2021-02-24 IL IL281067A patent/IL281067B/en unknown
- 2021-03-23 AU AU2021201811A patent/AU2021201811B2/en active Active
- 2021-08-31 AU AU2021225162A patent/AU2021225162B2/en active Active
- 2021-08-31 AU AU2021225161A patent/AU2021225161B2/en active Active
- 2021-10-05 ZA ZA2021/07472A patent/ZA202107472B/en unknown
- 2021-10-05 ZA ZA2021/07471A patent/ZA202107471B/en unknown
- 2021-11-12 US US17/525,350 patent/US11826351B2/en active Active
2022
- 2022-06-07 JP JP2022092275A patent/JP7419437B2/en active Active
2023
- 2023-07-31 US US18/362,249 patent/US20230372298A1/en active Pending
2024
- 2024-02-27 HU HUS2400003C patent/HUS2400003I1/en unknown
- 2024-03-01 FI FIC20240004C patent/FIC20240004I1/en unknown

Also Published As

Publication number	Publication date
CN114591242A (en)	2022-06-07
SG11201805044WA (en)	2018-07-30
MX2018007267A (en)	2018-11-09
AU2021225162B2 (en)	2023-08-03
MA55064A (en)	2021-09-29
IL276283A (en)	2020-09-30
US20230372298A1 (en)	2023-11-23
MX2021003478A (en)	2022-07-25
RS60982B1 (en)	2020-11-30
MD3390395T2 (en)	2021-02-28
JP2018538307A (en)	2018-12-27
CN114634447A (en)	2022-06-17
ZA201804137B (en)	2022-08-31
CR20180367A (en)	2018-11-12
CN113636978A (en)	2021-11-12
JP2022120013A (en)	2022-08-17
HUS2400003I1 (en)	2024-03-28
IL281067B (en)	2022-04-01
PE20220507A1 (en)	2022-04-07
KR20210018530A (en)	2021-02-17
FIC20240004I1 (en)	2024-03-01
CY1123561T1 (en)	2022-03-24
UA127863C2 (en)	2024-01-31
AU2021201811B2 (en)	2022-01-27
HK1263254A1 (en)	2020-02-21
JP2020172535A (en)	2020-10-22
US20190000806A1 (en)	2019-01-03
DK3390395T3 (en)	2020-09-28
CN108473481B (en)	2022-04-19
EA035132B1 (en)	2020-04-30
WO2017103611A1 (en)	2017-06-22
ES2828431T3 (en)	2021-05-26
ZA202107472B (en)	2023-03-29
US20190135762A1 (en)	2019-05-09
IL259923B (en)	2020-08-31
LT3390395T (en)	2020-11-25
PT3390395T (en)	2020-11-03
KR20180115261A (en)	2018-10-22
CN108473481A (en)	2018-08-31
IL285976B1 (en)	2023-06-01
SI3390395T1 (en)	2020-11-30
AU2021225161B2 (en)	2023-08-03
CN114716381A (en)	2022-07-08
IL276283B (en)	2021-03-25
AU2021201811A1 (en)	2021-04-22
IL285976B2 (en)	2023-10-01
EA201891268A1 (en)	2018-11-30
CN114621146A (en)	2022-06-14
CO2018006164A2 (en)	2018-09-20
JP7086140B2 (en)	2022-06-17
PE20220502A1 (en)	2022-04-07
PH12018501268A1 (en)	2019-02-18
CA3008488C (en)	2023-10-10
AU2016373530A1 (en)	2018-07-05
MA49809A1 (en)	2021-08-31
BR112018012341A2 (en)	2018-12-04
JP6731483B2 (en)	2020-07-29
IL281067A (en)	2021-04-29
US20180362512A1 (en)	2018-12-20
US10918622B2 (en)	2021-02-16
IL259923A (en)	2018-07-31
US10464905B2 (en)	2019-11-05
TN2018000213A1 (en)	2019-10-04
EP3782994A1 (en)	2021-02-24
AU2016373530B2 (en)	2021-01-21
CN114605327A (en)	2022-06-10
PE20181449A1 (en)	2018-09-12
AU2021225161A1 (en)	2021-09-30
US11826351B2 (en)	2023-11-28
NZ743553A (en)	2022-08-26
ZA202107471B (en)	2023-03-29
CN113603645A (en)	2021-11-05
UA122258C2 (en)	2020-10-12
CA3008488A1 (en)	2017-06-22
EP3390395B1 (en)	2020-09-09
US20220062239A1 (en)	2022-03-03
AU2021225162A1 (en)	2021-09-30
EP3390395A1 (en)	2018-10-24
CN114573510A (en)	2022-06-03
US10695323B2 (en)	2020-06-30
CL2018001591A1 (en)	2018-09-28
JP7419437B2 (en)	2024-01-22
US10342780B2 (en)	2019-07-09
US20200276162A1 (en)	2020-09-03
US11471441B2 (en)	2022-10-18
IL285976A (en)	2021-10-31
US20210093611A1 (en)	2021-04-01
KR102215792B1 (en)	2021-02-16
ZA202100544B (en)	2023-06-28
HRP20201835T1 (en)	2021-01-08
HUE051921T2 (en)	2021-03-29

Publication	Publication Date	Title
HUS2400003I1 (en)	2024-03-28	Compounds useful as kinase inhibitors
ZA201700115B (en)	2020-05-27	Aminopyridazinone compounds as protein kinase inhibitors
PL3371190T3 (en)	2022-11-07	Heterocyclic compounds as pi3k-gamma inhibitors
IL255750A (en)	2018-01-31	Heterocyclic compounds as kinase inhibitors
IL268614B (en)	2021-12-01	Aminotriazolopyridines as kinase inhibitors
IL274207B (en)	2022-12-01	Aminoimidazopyridazines as kinase inhibitors
IL266789A (en)	2019-07-31	Heterocyclic compounds as kinase inhibitors
IL266150A (en)	2019-06-30	Amide compounds as kinase inhibitors
EP3102571A4 (en)	2016-12-14	Substituted pyrimidines useful as egfr-t790m kinase inhibitors
HK1253576A1 (en)	2019-06-21	Pyrropyrimidine compounds as mnks inhibitors
GB201613945D0 (en)	2016-09-28	Compounds useful as kinase inhibitors
GB201522245D0 (en)	2016-02-03	Compounds useful as kinase inhibitors
GB201519382D0 (en)	2015-12-16	Kinase inhibitors
GB201519381D0 (en)	2015-12-16	Kinase inhibitors